Riboflavin 5'-Phosphate · ophthalmic kit
Misc.
Approved uses
Keratoconus in patients aged 13 and over
Mucin layer removed with an EPIOXA HD soaked sponge without debriding the epithelium; two drops of EPIOXA HD every 60 seconds for 4 minutes, then two drops of EPIOXA every 30 seconds for 6 minutes, followed by UV-A irradiation with the O2n System and Boost Goggles
Epithelium-ON: the epithelium stays, so recovery is faster and far less painful than the Photrexa protocol
Contraindications
- Known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA
- Aphakic patients, and pseudophakic patients without a UV-blocking intraocular lens
Kit with one 2 mL single-dose glass syringe each of EPIOXA HD 0.239% and EPIOXA 0.177%, for use only with the O2n System and Boost Goggles
Riboflavin 5'-phosphate sodium (Vitamin B2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. Under the conditions used for corneal collagen cross-linking, riboflavin 5'-phosphate functions as a photoenhancer and generates singlet oxygen which is responsible for the cross-linking.
Warnings & Precautions
Herpetic keratitis: use with caution in patients with a history of herpetic keratitis, because cross-linking may reactivate it.
Common Side Effects
The most common adverse reaction was conjunctival hyperemia (31%). Other adverse reactions occurring in 5% to 25% of CXL-treated eyes included corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, lacrimation increased, corneal epithelium defect, eyelid edema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.
Pregnancy: Animal development and reproduction studies have not been conducted. It is not known whether the epithelium-on corneal collagen cross-linking procedure can cause fetal harm or affect reproduction capacity, so it should not be performed on pregnant women.
Lactation: There are no data on the presence of EPIOXA HD or EPIOXA in human milk, the effects on the breastfed infant, or the effects on milk production. Consider the benefits of breastfeeding along with the mother's clinical need for the procedure and any potential adverse effects on the breastfed child.
The safety and effectiveness of EPIOXA HD and EPIOXA for the treatment of keratoconus have been established in pediatric patients aged 13 years and older.